Coeptis Therapeutics (NASDAQ: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, was spotlighted in the peer-reviewed “Journal of Translational Medicine.” The company’s SNAP-CAR technology was recognized in an article that detailed advances in modulating chimeric antigen receptor (“CAR”)-T cell activity for improved safety, efficacy and flexibility. SNAP-CAR is a multiantigen chimeric antigen receptor T cell technology that can be adapted to different cancer indications, including hematologic and solid tumors. Titled “Tuning CARs: Recent Advances In Modulating Chimeric Antigen Receptor (‘CAR’) T Cell Activity for Improved Safety, Efficacy and Flexibility,” the article outlined the efforts and collaborations that are working to balance antitumor activity of next-generation cell therapies, which also minimize harmful side effects associated with CAR-T. The article describes SNAP-CAR as an “up-and-coming” technology that covalently links therapeutic monoclonal antibodies (“mAbs”) to CAR receptors. “We are pleased that SNAP-CAR was featured in this peer-reviewed article, which highlights the latest developments in CAR-T technologies designed to improve cell therapy outcomes and mitigate associated toxicities to enable improved safety, efficacy, and flexibility,” said Coeptis Therapeutics president and CEO Dave Mehalick in the press release. “Research conducted at the University of Pittsburgh suggests that SNAP-CAR offers an opportunity to direct the power of CAR T to an array of cancers that have, until now, been inaccessible via current cell therapy technologies by providing a highly programmable antigen targeting platform. SNAP-CAR T cells can be engineered to address numerous cancers, including HER2-expressing ovarian cancer, which we are targeting as our potential first-in-human clinical development program.”
To view the full press release, visit https://ibn.fm/Wrqi3
About Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics, together with its subsidiaries including Coeptis Therapeutics Inc. and Coeptis Pharmaceuticals Inc., is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis product portfolio and rights are highlighted by a universal, multiantigen CAR-T technology licensed from the University of Pittsburgh (SNAP-CAR), and a cell-therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institute. Coeptis’ business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. For more information about the company, please visit www.Coeptistx.com.
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
BioMedWire is part of the InvestorBrandNetwork.